Pulse Biosciences Inc Dossier
|
SectorHealth Care IndustryMedical Instruments & Supplies Beta (adjusted)1.39 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $49.83Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $3.6B Enterprise Value $3.5B Shares Outstanding 68.8M diluted Next Earnings Date16 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Pulse Biosciences is a highly innovative medical technology company leveraging its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology to disrupt the cardiac ablation and soft tissue ablation markets. By delivering electrical pulses in nanoseconds rather than microseconds, the company's nPulse platform achieves regulated cell death while sparing non-cellular tissue, offering superior safety, speed, and efficacy compared to existing thermal and microsecond PFA systems. With FDA IDE approvals secured for both its cardiac catheter (NANOPULSE-AF) and surgical clamp (NANOCLAMP AF) programs, and initial product revenues commencing, Pulse is transitioning from a pure R&D entity to a commercial-stage clinical powerhouse. Backed by strong insider buying and a robust balance sheet with over $68 million in cash, the company is well-positioned to achieve major clinical and regulatory catalysts through 2026 and 2027. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$35.00 Mean target$41.00 High · most bullish analyst$45.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $35.0020% Clinical trial enrollment faces delays due to intense competition in the crowded PFA market from established players like Medtronic and Boston Scientific. Regulatory submissions are pushed back, and the lack of immediate large-scale commercial revenue accelerates cash burn, forcing dilutive equity financing or debt accumulation. Base CaseCentral scenario $41.0050% Matches the consensus meanPulse Biosciences executes its clinical trials within the projected timelines, completing enrollment for the NANOPULSE-AF study by late 2026. The company submits its CE Mark application in the second half of 2026 as planned, with potential approval in 2027. Vybrance commercialization progresses under a highly controlled rollout, and the company maintains tight cost controls to preserve its cash runway. Bull CaseUpside scenario $45.0030% Rapid enrollment in the NANOPULSE-AF and NANOCLAMP AF trials leads to early clinical data readouts in late 2026, demonstrating superior safety and 100% procedural success. The company secures CE Mark approval ahead of schedule in early 2027, and the Vybrance platform achieves rapid commercial adoption with clear reimbursement pathways, driving exponential revenue growth. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |